Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 14/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7173085 | 0.83 | KDR (0.64) | GRM4HDAC6RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6278943 | 0.83 | GRM4 (1.00) | GRM4HDAC6RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22217154 | 0.82 | GRM4 (0.66) | GRM4HDAC6RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22208893 | 0.81 | GRM4 (0.66) | GRM4HDAC6RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24298574 | 0.81 | GRM4 (0.65) | GRM4HDAC6RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22216946 | 0.80 | GRM4 (0.78) | GRM4HDAC6RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22216944 | 0.79 | GRM4 (0.76) | GRM4HDAC6RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22209135 | 0.79 | NPC1 (0.72) | GRM4RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL23705777 | 0.78 | GRM4 (1.00) | GRM4HDAC6RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29412182 | 0.78 | GRM4 (1.00) | GRM4HDAC6RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220118117-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | MASSACHUSETTS GEN HOSPITAL (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118117-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | GRM2, GRM4, GRM1 | GRM4 2/4885HDAC6 2334/4885RAB9A 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.